Benefits
Self-reported energy and focus (not measured performance)
In the single trial of methylliberine on its own (25 healthy men and women, 100 mg a day, manufacturer funded), people rated their energy, concentration and motivation higher than on placebo in the 1 to 3 hours after a dose. Those were self-ratings on a sliding scale. In the same session, the objective tests of attention and task switching (Stroop, Trail Making Test-B) showed no advantage over placebo, and the study's authors concluded plainly that methylliberine did not improve cognitive function. The 15 to 30 minute onset figure, and the comparisons with caffeine and TeaCrine onset times, come from product marketing rather than from any study cited here.
No rise in heart rate or blood pressure in short studies
In a randomized safety study in young adults (100 mg or 150 mg a day, alone or with 50 mg TeaCrine) and in the 25-person trial described below, methylliberine did not raise heart rate, blood pressure or ECG readings compared with placebo, and standard blood tests were unchanged. Both studies were short and enrolled healthy people, so they say nothing about long-term use or about people with heart or blood pressure conditions. If you are sensitive to stimulants or take heart or blood pressure medication, check with your doctor first.
Usually sold with caffeine, but the half-life claim is unpublished
A pharmacokinetic study said to show that Dynamine roughly doubles caffeine's half-life is quoted throughout the supplement industry, but no such study appears in this page's reference list and we have not found a published version, so treat it as an unverified manufacturer claim. What has actually been published are two trials of the blend: one in tactical personnel and one in adult male egamers, both giving caffeine, methylliberine and theacrine together. Studies of a three-ingredient blend cannot show what methylliberine adds on its own, and neither one measured caffeine levels in the body.
Mood elevation and motivation
This is the best-supported effect on the page, though it rests on one small study. In 25 healthy adults, 100 mg of methylliberine improved self-rated mood by roughly 10 to 16 percent and self-rated motivation by about 16 percent at 3 hours compared with placebo, and the effects lasted longer than placebo. The dopamine explanation is a theory borrowed from related compounds, not something measured in these participants, and the same study found no improvement in measured thinking or task-switching performance. The trial was small, lasted 4 days, and was paid for by the ingredient's maker.
Mechanism of action
Adenosine receptor antagonism and dopamine modulation
Methylliberine blocks adenosine A1 and A2A receptors — the same primary mechanism as caffeine — preventing adenosine-driven fatigue signaling and maintaining dopaminergic tone. Greater activity at dopamine D2 receptors has been proposed to explain the better mood and motivation ratings people report, but none of the studies cited here measured receptor activity in humans, so this remains a working theory rather than an established fact.
Clinical trials
Randomized, double-blind, placebo-controlled safety study of methylliberine (Dynamine®, 100 mg or 150 mg/day) alone and in combination with TeaCrine® (theacrine, 50 mg) in healthy adults over 8 weeks. Outcomes: clinical safety markers (hematology, blood chemistry, lipids, blood pressure, heart rate, ECG). (VanDusseldorp et al. 2020, J Diet Suppl)
Healthy adults. 8-week safety study.
Dynamine® alone and combined with TeaCrine® showed no adverse effects on heart rate, blood pressure, ECG parameters, or standard hematological/biochemical markers vs placebo. Generally well-tolerated. Note: this is primarily a safety trial — does not establish efficacy claims.
Randomized, double-blind, placebo-controlled crossover trial of methylliberine on its own, published in Nutrients in 2023 and funded and co-authored by the ingredient's maker, Compound Solutions (La Monica et al. 2023, PMID 37960163). The paper's own title says methylliberine improved several measures of affect but not cognitive function.
25 healthy men and women (33.5 ± 10.7 yr; 13 women, 12 men). Double-blind, randomized, within-subject crossover trial; 100 mg methylliberine (Dynamine™) vs placebo for 3 days. On day 4, fourth dose taken in lab; testing at baseline and 1, 2, 3 hours post-ingestion. Stroop, Trail Making Test-B (TMT-B), and validated VAS for energy/mood/concentration. NCT06048640. Funded by Compound Solutions.
Methylliberine had no significant effect on measured cognitive function (Stroop and Trail Making Test-B versus placebo, p greater than 0.05); placebo and Dynamine improved to a similar degree simply from practice. However, Dynamine significantly improved subjective ratings of concentration (+15.3% at 3h vs PLA), motivation (+15.8% at 3h), and mood (+9.8 to 16.4% across 1-3h, all p<0.05) and sustained these effects longer than placebo. Sex-specific finding: women (lower body weight, higher mg/kg) showed greater energy and sustained energy gains at 1h and 3h with Dynamine vs placebo. No vital sign elevations; no adverse events. Distinguishes Dynamine from caffeine in not raising BP. Half-life ~1.5 hr. This is the only published trial of methylliberine by itself; every other human study combined it with caffeine and theacrine. It was small (25 people), ran for 4 days, and was funded and co-authored by the manufacturer, so it needs independent replication.